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Abstract
Huntington’s disease (HD) is a progressive neurodegenerative disease caused by an unstable CAG trinucleotide repeat
expansion. The need for biomarkers of onset and progression in HD is imperative, since currently reliable outcome measures
are lacking. We used two-dimensional electrophoresis and mass spectrometry to analyze the proteome profiles in
cerebrospinal fluid (CSF) of 6 pairs of HD patients and controls. Prothrombin, apolipoprotein A-IV (Apo A-IV) and
haptoglobin were elevated in CSF of the HD patients in comparison with the controls. We used western blot as a semi-
quantified measurement for prothrombin and Apo A-IV, as well as enzyme linked immunosorbent assay (ELISA) for
measurement of haptoglobin, in 9 HD patients and 9 controls. The albumin quotient (Qalb), a marker of blood-brain barrier
(BBB) function, was not different between the HD patients and the controls. The ratios of CSF prothrombin/albumin
(prothrombin/Alb) and Apo A-IV/albumin (Apo A-IV/Alb), and haptoglobin level were significantly elevated in HD. The ratio
of CSF prothrombin/Alb significantly correlated with the disease severity assessed by Unified Huntington’s Disease Rating
Scale (UHDRS). The results implicate that increased CSF prothrombin, Apo A-IV, and haptoglobin may be involved in
pathogenesis of HD and may serve as potential biomarkers for HD.
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Introduction
Huntington’s disease (HD) is a progressive neurodegenerative
disease with autosomal dominant inheritance, characterized by
cognitive decline, movement disorder and different psychiatric
manifestations. It is caused by an unstable CAG trinucleotide
repeat expansion in the gene encoding huntingtin protein [1]
resulting in neuronal dysfunction and death predominantly in the
striatum and cortex [2]. Several pathogenic mechanisms have
been identified, including neuronal aggregation of the mutated
protein [3], transcriptional dysregulation [4], excitotoxicity [5],
altered energy metabolism [6,7], mitochondrial dysfunction [8,9],
impaired axonal transport, and altered synaptic transmission
[10,11].
Therapeutic strategies that prevent HD progression are not
available yet. While many potential beneficial treatments have been
reported in cell or/and animal models, reliable pre-symptomatic/
symptomatic biomarkers that can indicate the disease status and test
the therapeutic efficacy are lacking. Because cerebrospinal fluid
(CSF) is located around and insidethe brain,biomarkers originating
from it may provide insights into the disease pathophysiology and
severity as well as monitoring responses to the preventive, disease-
modifying, and symptomatic therapies.
Fang and colleagues reported an extensive list of proteins
identified in HD CSF relative to control using current proteomics
technology, supporting the idea of CSF as a rich source of
biomarkers [12]. In several reports, plausible evidence supports an
increased activity of transglutaminases in HD that generates
elevated levels of c-glutamyl-e-lysine cross-links and c-glutamyl-
polyamine residues in CSF [13,14]. However, the c-glutamyl-e-
lysine cross-links are also elevated in Alzheimer’s disease (AD) and
vascular dementia [15], indicating that increased transglutaminase
activity is a common phenomenon in a variety of neurodegener-
ative disease and not specifically for HD [16]. In another study,
F2-isoprostane, a marker of oxidative stress, was increased in CSF
from HD patients, but the level was not correlated with disease
duration [17]. Cocaine- and amphetamine-regulated transcript
(CART) was also elevated in CSF of HD patients, probably
reflecting the hypothalamic lesion in regulating energy homeosta-
sis and emotion, but the level was not correlated to CAG repeat
length, body mass index, or other clinical features [18]. CSF
neurofilament was increased in HD subjects and was correlated
with scores on the Unified Huntington’s Disease Rating Scale
(UHDRS) total functional capacity [19]. Clusterin, inteleukin 6
(IL-6), and interleukin 8 (IL-8) in both serum and CSF were up-
regulated and correlated to disease severity, indicating a neuroin-
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CSF proteins identified in HD by Fang and colleagues [12], a
subsequent study has not been conducted yet to further verify the
differentially-expressed protein molecules as reliable biomarkers.
Given that valid CSF biomarkers that are specific for HD and
correlated with disease severity are imperative, we set out to use
clinical proteomics to investigate the CSF protein profile of HD
patients, which may be helpful to shed light on the pathophys-
iology of HD and to identify potential biomarkers.
Materials and Methods
CSF specimen and preparation
CSF and serum samples were collected from 9 HD (5 males, 4
females, Table 1) patients who were recruited from neurological
clinicofChangGungMemorialHospitalandgeneticallydiagnosed.
The UHDRS of eachpatient was assessed by clinicians (Yih-Ru Wu
and Chiung-Mei Chen) in outpatient clinics before the CSF and
serum were collected and investigated for proteomic profile.
Therefore, the clinicians who assessed the UHDRS did not know
the CSF results before scoring. The proteomic studies of CSF
samples were subsequently performed by a different person, who
was blinded to the identity and the disease severity of each patient.
CSF and serum samples from 18 controls (7 males, 11 females,
Table 1) were collected from patients with other neurological
diseases who were admitted due to migraine, tension headache,
spontaneous intracranial hypotension, amyotrophic lateral sclerosis,
and degenerative spine diseases. These control patients had no
systemic infection; chronic renal, cardiac or liver dysfunction;
autoimmune diseases; or malignancies. The 18 controls were
divided into 4 groups with one for two-dimensional electrophoresis
(2-DE) and the other overlapping three for quantification of
prothrombin, Apo-A IV, and haptoglobin. Body mass index (BMI)
was calculated by weight in kilograms divided by squared height in
meters for each individual. The examination of the control and HD
CSF samples also showed an absence of inflammation (no
pleocytosis). Venous blood was obtained simultaneously with the
CSF sampling for each subject. White blood cell counts, and
albumin concentration of the CSF and serum were analyzed
automatically using Synchron LXH20 PRO (Beckman Coulter,
Brea, California, USA) by the Department of Clinical Pathology,
Chang Gung Memorial Hospital. The albumin quotient (Qalb) was
derived from CSF albumin/serum albumin, where the CSF or
serum albumin was an absolute concentration. This study was
performed under a protocol approved by the institutional review
boards of Chang Gung Memorial Hospital (ethical license No: 98-
0125C) and all examinations were performed after obtaining
written informed consents.
CSF samples were centrifuged immediately after collecting to
eliminate cells and other insoluble material, aliquoted and stored
at 280uC until analysis. Blood samples were kept at 4uC for 1 h
and then centrifuged. The serum was aliquoted and stored at
280uC until analysis.
UHDRS
UHDRS [22] including motor score, independence scale, and
functional capacity, was used to assess the severity of HD (Table 1).
Worse severity of HD scores higher in motor score and lower in
independence scale and functional score.
2-DE
CSF samples were cleaned up by ReadyPrep 2-DE Clean-Up
Kit (Bio-Rad, Herculus, CA) following the manufacturer’s
instruction. Briefly, each CSF sample was first mixed with 3-fold
volume of precipitation agent 1 and kept on ice for 15 min, and
then 3-fold sample volume of precipitation agent 2 was added. The
mixture was centrifuged at 19,0006g for 5 min. The pellet was
washed by wash reagent 1 and centrifuged again. After the pellet
was re-suspended with distilled water, pre-chilled wash reagent 2
and wash reagent 2 additive were added. The mixture was
incubated at 220uC for 30 min and vortexed every 10 min
followed by a centrifugation at 19,0006g for 5 min. The protein
pellets were solubilized in rehydration buffer (85 mM DTT, 1.4%
biolyte pH 3–10, 4.4 M urea, 1.8 M thiourea, 3.5% CHAPS).
Each sample containing 350 mg of protein was diluted to 330 ml
with rehydration buffer and kept at room temperature for 2 h.
The isoelectric focusing electrophoresis (IEF) was performed with
pH 3–10 nonlinear immobilized pH gradient (IPG) strips (Bio-
Rad, Herculus, CA) at 18uC as the following steps: active
rehydration at 50 V for 16 h, then fast to 300 V for 1h, slow to
3500 V for 3h, kept at 3500 V for 3h, finally fast to 8000 V until
achieved 63000 Vh. After IEF, the strip was equilibrated with
equilibration buffer (6 M urea, 30% glycerol, 2% SDS) containing
2% DTT for 15 min at room temperature, and then incubated
with 2.5% IAA in equilibration buffer for another 15 min. The
secondary dimensional separation was performed using 11.5%
SDS polyacrylamide gel electrophoresis (SDS-PAGE).
Protein visualization and image analysis
The 2-DE gels were fixed with 7% acetic acid and 10%
methanol for 60 min followed by staining in a SYPRO Ruby
solution (Molecular Probes, Eugene, OR) for 6 h. After that, gels
were washed for 10 h with 7% acetic acid and 10% methanol to
remove the background, and then stored in distilled water at 4uC.
Gels were scanned by a ProXPRESS 2D Proteomic Imaging
System (PerkinElmer, MA, USA) at excitation/emission values of
460 nm/650 nm and resolution of 100 mm. Gel images were
analyzed by Progenesis software (Nonlinear Dynamics, Durham,
NC) and a cut-off value 1.5-fold change of spot normalized volume
was used to be an estimation of significant difference.
Table 1. Clinical characteristics of the Huntington’s disease
(HD) patients and the controls.
Controls (n=18) HD patients (n=9)
Gender (male/female) 7/11 5/4
Age (years) 45.863.0 (26–64)
# 43.463.4 (25–57)
Age at symptom onset
(years)
38.964.0 (15–53)
Body mass index 23.460.8 21.061.1*
Disease duration (years) 4.961.0 (2–10)
Expanded CAG repeat No 46.162.3 (41–62)
UHDRS
Motor score 32.267.4 (9–69)
Independence scale 78.966.6 (40–100)
Functional capacity 9.261.2 (3–13)
Values are expressed as means 6 SE (range; minimum–maximum).
UHDRS: The Unified Huntington’s Disease Rating Scale. Scale ranges (normal to
most severe) include motor score (0 to 124), independence score (100 to 10),
and functional capacity (13 to 0).
#Three different groups from controls (9 in each group) were compared with 9
HD patients for prothrombin/Alb, Apo A-IV/Alb, and haptoglobin, respectively
(The ages of the 3 groups were 41.764.3, 45.764.7, and 41.164.1).
*P=0.09.
doi:10.1371/journal.pone.0015809.t001
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The interesting spots were cut from 2-DE gel. The gel particles
were incubated in 25 mM NH4HCO3 buffer containing 55 mM
DTT, pH 8.5, for 1 h at 37uC and then incubated in 25 mM
NH4HCO3 containing 100 mM IAA, pH 8.5, for 1 h at 37uCi n
dark. After washing twice with 25 mM NH4HCO3/50% aceto-
nitrile for 15 min, gel particles were dehydrated with acetonitrile
followed by rehydration with trypsin solution (5 mlo f2 5 m M
NH4HCO3, pH 8.5, containing 20 ng trypsin) and then incubated
at 37uC for 16 h. The peptides were extracted by 5% TFA in 50%
acetonitrile and analysis by mass spectrometry.
Mass spectrometry (MS) analysis and protein
identification
Matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS) analyses were performed using
an Ultraflex MALDI-TOF MS instrument (Bruker Daltonics).
Samples were premixed with matrix solution (1 mg/ml a-Cyano-
4-hydroxycinnamic acid (CHCA) in 70% acetonitrile, 0.1% v/v
TFA) at 1:1 ratio and spotted onto the AnchorChip. A nitrogen
laser (wave length, 337 nm) operating at 20 Hz was used for
ionization. For matrix suppression, a gating factor with signal
suppression up to 800 Da was performed. A calibration mixture of
known peptides/proteins in a mass range of 1,000,25,000 Da
was set for mass calibration. To increase detection sensitivity,
excess matrix was removed with ten shots at a laser power of 60%
before data acquisition. Fifty laser shots at three different spot
positions were acquired in each spectrum. All of the peaks with S/
N.5 in a mass range of 1,000,25,000 Da were recorded using
the AutoXecute tool of the flexControl acquisition software
(Version 2.0, Bruker Daltonics).
Matrix-assisted laser desorption/ionization time-of-flight tan-
dem mass spectrometry (MALDI-TOF MS/MS) analyses were
performed by a dedicated Q-Tof Ultima
TM MALDI instrument
(Micromass, Manchester, UK) and the systems were operated
under MassLynx 4.0 and raw MS data were processed for
database searching using ProteinLynx Global Server 2.0. Each
sample was premixed 1:1 with matrix solution (5 mg/ml CHCA in
50% acetonitrile, 0.1% v/v TFA and 2% w/v ammonium citrate)
and spotted onto the 96 well formats MALDI sample stage. Within
each well, peaks of parent ions which were within the m/z
800,3,000 range with intensity above 10 counts 6 include/
exclude list will be selected automatically for collision-induced
dissociation (CID) MS/MS using argon as collision gas and a mass
dependent 65V rolling collision energy until end of probe pattern
was reached, starting from the most intense peak. The low mass
and high mass resolution of the quadrupole were both set at 10 to
give a precursor selection window of about 4 Da wide. The
instrument was externally calibrated to less than 5 ppm accuracy
over the mass range of m/z 800,3,000. At a laser firing rate of
10 Hz, individual spectra from 5 second integration period
acquired for each of the MS survey and MS/MS performed were
combined, smoothed, deisotoped (fast option), and centroided
using the Micromass ProteinLynx
TM Global Server (PGS) 2.0 data
processing software. The combined PMF and MS/MS ion meta
data were searched against the specified protein database within
the PGS 2.0 workflow.
The resulting peptide data from both mass and tandem mass
were searched against SWISS-PROT database using MASCOT
software on the matrixscience website (www.matrixscience.com).
Matching peptides with one missed cleavage were considered as
adequacy. For MS data searching, a mass deviation of 50 and
75 ppm was allowed. For MS/MS ion searching, a 50 ppm
peptide mass tolerance and 0.6 Da ms/ms tolerance was applied.
Western blot analysis
Equal amount protein of each CSF or serum sample from 9 HD
patients and 9 controls was mixed with sample buffer (Invitrogen,
Carlsbad, CA) and reducing agent (Invitrogen, Carlsbad, CA).
Each sample was heated at 70uC for 10 min, and then separated
by NuPAGE Novex Bis-Tris 4–12% gel (Invitrogen, Carlsbad,
CA) and transferred to polyvinylidene fluoride (PVDF) mem-
branes (Millipore, Billerica, MA). After overnight blocking, the
membranes were incubated with 1 mg/ml anti-prothrombin rabbit
polyclonal antibody (Abnova, Taipei, Taiwan) or anti-prothrom-
bin mouse polyclonal antibody (Abnova, Taipei, Taiwan) at 1:
1000 dilution, anti-apolipoprotein A-IV (Apo-A IV) polyclonal
antibody (Abnova, Taipei, Taiwan) at 1:2000 dilution in Tris
buffer saline containing 0.05% Tween 20 (16TBST) for 3 h, and
anti-albumin antibody (Sigma, Saint Louis, MO) at 1:200,000
dilution in 16TBST for 2 h. The membranes were washed and
incubated in 16 TBST containing horseradish peroxidase
conjugated goat anti-mouse IgG secondary antibody or donkey
anti-rabbit IgG secondary antibody (Pierce, Rockford, IL) for 2 h.
For membranes stained with mouse anti-prothrombin and anti-
Apo A-IV primary antibody, 0.04 mg/ml secondary antibody was
applied; for membranes stained with rabbit anti-prothrombin
primary antibody, 0.013 mg/ml secondary antibody was applied;
for membranes stained with anti-albumin primary antibody,
0.002 mg/ml secondary antibody was added. Immuno-reactive
bands were visualized with SuperSignal West Pico Chemilumi-
nescent Substrate (Pierce, Rockford, IL) and detected with Kodak
BioMax light film. The resulting bands were scanned and
measured for density using Image Pro software (Image Pro Plus
5.0, Media Cybernetics, MD). Western blot experiments for both
Apo A-IV and prothrombin were performed in triplicate to reduce
experimental error and the mean was used in statistical analysis.
The level of prothrombin and Apo A-IV in CSF or serum was
expressed as the ratio of prothrombin and Apo A-IV over albumin
density in each sample on the western blot (prothrombin/Alb and
Apo A-IV/Alb, respectively).
Enzyme linked immunosorbent assay (ELISA) for
haptoglobin
CSF and serum haptoglobin levels were assessed by AssayMax
ELISA Kit (Assaypro, Winfield, MO, USA) according to the
manufacturer’s instruction.
Statistical analysis
All statistical analyses were performed using Statistical Program
for Social Sciences (SPSS) statistical software (version 16, Chicago,
IL, USA). For each set of values, data were expressed as mean 6
standard error (SE) or median (interquartile range) where
appropriate. Differences in spot intensities in 2-DE gels between
HD patients and controls were analyzed by the paired Student’s t-
test. Mann-Whitney U test was used to examine the differences
between HD patients and controls in BMI, prothrombin/Alb, Apo
A-IV/Alb, and haptoglobin concentration in CSF and serum.
Spearman correlation was used to test if the examined protein
levels were correlated with age. Mann-Whitney U test was used to
examine if the protein levels were affected by gender. Linear
regression analysis was applied to evaluate the correlation of each
subscale in UHDRS to Apo A-IV/Alb, prothrombin/Alb, and
haptoglobin concentration in CSF, respectively. The correlation of
BMI with Apo A-IV/Alb in CSF of HD patients was also analyzed
by linear regression. A p,0.05 was considered statistically
significant. The present sample sizes achieve a power of 71%,
94%, and 80% for haptoglobin, Apo A-IV/Alb, and prothrom-
CSF Biomarkers in Huntington’s Disease
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control group and that of case group with the estimated standard
deviations at the level of 0.05.
Results
CSF proteome profile in HD patients and controls
We investigated the proteome profile in CSF of 6 HD patients
(age, 4264.8) and 6 age-matched controls (age, 44.463.21) using
gel-based proteomics technology. The disease and control samples
were aligned randomly to get pairs for 2-DE gel analysis. A
representative pair of resulting 2-DE gels was shown in figure 1.
There were at least three protein spots (spots 1–3) expressed at
higher level on the gel of CSF from the HD patient (Fig. 1A)
compared to the corresponding control (Fig. 1B). Although some
other protein spots expressed at differential level between HD and
control CSF, we only showed the protein spots whose volume after
normalization (spot volume over total spots volume on the gel,
analyzed by Progenesis software) have at least 1.5-fold change in at
least four pairs of specimens, or P,0.05 analyzed by paired t-test.
MALDI-TOF MS and MALDI-TOF MS/MS were applied to
identify the proteins corresponding to these three spots (Table 2).
The three up-regulated proteins in HD CSF were prothrombin,
Apo A-IV, and haptoglobin. The cropped images of these three
spots from 2-DE maps of six sample pairs are shown in Figure 1C.
The expression level of prothrombin, spot 1 in Fig. 1, was 1.66-fold
higher in HD versus control samples, which was found in five of six
comparisons (p=0.003). Another up-regulated protein, Apo A-IV
(spot 2 in Fig. 1) was 1.67-fold increased in CSF of the HD patients,
and the Apo A-IV level was higher in four HD samples compared
with the controls (p=0.004). The haptoglobin (spot 3 in Fig. 1) level
revealed a 1.96-fold increase in HD group compared with the
controls, which was found in five of six comparisons (p=0.007).
Increased prothrombin, Apo A-IV and haptoglobin levels
in CSF of HD patients
The increased levels of CSF prothrombin, Apo A-IV, and
haptoglobin were further examined in 9 HD patients compared with
9 age-matched controls using western blot analysis or ELISA. The
levels of prothrombin in CSF and serum from 9 HD patients (age,
43.463.4) and 9 age-matched controls (age, 41.764.3) are shown in
Fig. 2. Age did not hasan effect on CSF prothrombin/Alb(p=0.90),
Apo A-IV/Alb(p=0.30), andhaptoglobin (p=0.65) levels. The CSF
prothrombin/Alb ratio (male, 0.30 [0.24 to 0.40]; female, 0.21 [0.17
to 0.27], p=0.05), Apo A-IV/Alb ratio (male, 0.12 [0.05 to 0.17];
female, 0.07 [0.06 to 0.10], p=0.16), and haptoglobin levels (male,
0.9 [0.24 to 2.67]; female, 0.42 [0.23 to 0.82], p=0.18) showed no
significant difference between male and female group. The
prothrombin/Alb ratio in CSF of HD patients (0.30 [0.21 to
0.40]) was increased compared with the controls(0.22 [0.16 to 0.26])
(p=0.048). The ratio of prothrombin/Alb in serum of HD patients
(0.30 [0.24 to 0.45]) was not different from those of controls (0.35
[0.30 to 0.43]). Albumin quotient (Qalb, CSF albumin/serum
albumin), a marker of blood-brain barrier (BBB) function revealed
no significant difference when comparing the HD patients (4.7 [4.1
to 6.6] *10
23) with the controls (4.0 [3.4 to 6.3]*10
23).
The Apo A-IV/Alb ratios in CSF and serum from 9 HD
patients (age, 43.463.4) and 9 age-matched controls (age,
45.764.7) are shown in Fig. 3. The ratio of Apo A-IV/Alb in
CSF of HD patients (0.12 [0.08 to 0.15]) was significantly higher
than that of controls (0.06 [0.03 to 0.09]) (p=0.005), while ratio of
Apo A-IV/Alb in serum of HD patients (0.23 [0.19 to 0.29]) was
not different from those of controls (0.31 [0.23 to 0.39]). The Qalb
were not different between HD patients (4.7 [4.1 to 6.6]*10
23) and
controls (3.4 [2.6 to 6.6]*10
23). CSF Apo A-IV/Alb ratio was not
correlated to BMI in HD patients. In order to know if the elevated
CSF Apo A-IV is specific to HD, we compared CSF Apo A-IV/
Alb ratios between 5 controls (0.058 [0.013 to 0.154]) and 5
patients with Guillain–Barre ´ syndrome (0.095 [0.055 to 0.126])
and there was no difference between them.
The haptoglobin levels in CSF and serum from 9 HD patients
(age, 43.463.4) and 9 age-matched controls (age, 41.164.1) are
shown in Fig. 4. CSF haptoglobin concentration of HD patients
(0.9 [0.48 to 2.50] mg/ml) was significantly higher than those of
controls (0.38 [0.22 to 0.53] mg/ml) (p=0.014), whereas
haptoglobin concentration in serum of HD patients (876 [799 to
Figure1.2-DEmapsofCSFproteomes.Representative2-DEmapsofCSFproteomefromapatientwithHD(A)andacontrol(B)areshown.Spots1–3
indicateproteinswithup-regulationinHD.Croppedimagescontainingspots correspondingtoprothrombin(spot1),apolipoproteinA-IV(ApoA-IV,spots
2) and haptoglobin (spot 3) (indicated by arrowheads) derived from 2-DE maps of six CSF samples of patients with HD and paired control samples (C).
doi:10.1371/journal.pone.0015809.g001
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1846] mg/ml). The Qalb was not different between HD patients
(4.7 [4.1 to 6.8]*10
23) and controls (4.0 [3.4 to 6.3]*10
23).
The correlation of prothrombin/Alb, Apo A-IV/Alb, and
haptoglobin concentration in CSF to UHDRS subscales,
respectively
The ratio of CSF prothrombin/Alb was significantly correlated
to subscales of UHDRS, with a positive correlation to motor score
(r=0.810, p=0.008) and a negative correlation to independence
scale (r=20.908, p,0.001) and functional capacity (r=20.891,
p=0.001), respectively (Fig. 5). However, there was no significant
correlation of the CSF Apo A-IV/Alb ratio to motor score
(r=0.394, p=0.294), independence scale (r=20.447, p=0.228)
and functional capacity (r=20.521, p=0. 151), as well as the CSF
haptoglobin concentration to motor score (r=20.047, p=0. 905),
independence scale (r=0.067, p=0.864) and functional capacity
(r=0.002, p=0.995). There was no significant correlation of the
CAG repeat numbers to CSF Apo A-IV/Alb ratio (r=0.539,
Table 2. Differentially-expressed protein molecules in CSF of Huntington’s disease (HD) patients.
Up-regulated proteins in CSF of patients with HD identified by MALDI-TOF MS
Spot
a) Accession No.
b) Protein name pI/M.W. Score
c)
Coverage
d)
(%)
Mean of fold
changes
e)
(HD/C)
Frequency
f),
P value
1 P00734 Prothrombin 5.64/69209 82 23 1.66 5/6, P=0.03
2 P06727 Apolipoprotein A-IV 5.28/45371 174 42 1.67 4/6, P=0.04
Up-regulated proteins in CSF of patients with HD identified by MALDI-TOF MS/MS
Spot
a) Accession No.
b) Protein name
Parent peak
mass Sequence Score
c)
Mean of fold
changes
e)
(HD/C)
Frequency
f),
P value
3 P00783 Haptoglobin 1722.7991 K.YVMLPVADQDQC
IR.H
51 1.96 5/6, P=0.07
a)Spots numbered as shown in Figure 1.
b)The accession numbers on SWISS-PROT database.
c)The MASCOT search score of identified proteins.
d)The percentage of sequence coverage of matched peptides in the identified protein.
e)The mean protein expression level in the HD patients over that in the controls in Figure 1C.
f)The frequency of the target protein, for which the expression ratio of HD/C was .1.5. P,0.05 indicates a significant difference in expression levels between HD
patients and controls analyzed by paired student’s t-test.
doi:10.1371/journal.pone.0015809.t002
Figure 2. Representative Western blots of prothrombin (72 kD) and albumin (64 kD) in CSF and serum of HD patients and their
corresponding controls (C). The resulting data are illustrated in scatter plots with median and interquartile range. The prothrombin/Alb ratio in
CSF of HD patients (n=9) is higher than that in controls (n=9). *p,0.05, Mann-Whitney U test.
doi:10.1371/journal.pone.0015809.g002
CSF Biomarkers in Huntington’s Disease
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e15809p=0.134), CSF prothrombin/Alb (r=0.644, p=0.061) and CSF
haptoglobin concentration (r=0.008, p=0.944).
Discussion
In this study, using 2-DE and MS analysis we have identified
three up-regulated protein molecules, prothrombin, Apo A-IV,
and haptoglobin, in CSF of HD patients in comparison with
controls. We have further used western blot analysis to measure
prothrombin and Apo A-IV levels and ELISA to measure
haptoglobin levels. The CSF prothrombin/Alb and Apo A-IV/
Alb ratios and haptoglobin concentration in HD patients were
increased, respectively, when compared with the controls.
Importantly, the CSF prothrombin/Alb ratio was significantly
correlated to the disease severity indicated by motor, indepen-
dence, and functional score of UHDRS.
Figure 3. Representative Western blots of Apo A-IV (46 kD) and albumin (64 kD) in CSF and serum, respectively, of HD patients and
their corresponding controls (C). The Apo A-IV/Alb ratios in CSF and serum in comparison with their corresponding control groups are illustrated
in scatter plots with median and interquartile rang, respectively. The Apo A-IV/Alb ratio in CSF of HD patients (n=9) is significantly higher when
compared with the controls (n=9). *p,0.01, Mann-Whitney U test.
doi:10.1371/journal.pone.0015809.g003
Figure 4. Qalb, CSF haptoglobin, and serum haptoglobin concentration in HD patients. Data are illustrated in scatter plots with median
and interquartile rang. Either the Qalb or serum haptoglobin concentration was not different between HD (n=9) and the controls (n=9), whereas the
CSF haptoglobin was significantly increased in HD. *p,0.05, Mann-Whitney U test.
doi:10.1371/journal.pone.0015809.g004
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PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e15809Prothrombin is synthesized in the liver as a precursor of
thrombin. It is cleaved into kringle-1 and kringle-2 domain and
active thrombin by prothrombinase [23], which is a crucial step in
the coagulation cascade [24]. Both prothrombin and thrombin
have been detected locally in the brain and may exert
physiological and pathological functions [25,26]. Thrombin can
signal via G protein-coupled protease-activated receptors (PARs)
[27] and has been considered as a potent mitogenic and
proinflammatory agent to microglia and astrocytes [28,29],
thereby regulating neuronal function. Prothrombin kringle-2
domain participates in cortical neuron death through microglial
NADPH oxidase-mediated oxidative stress [30]. Prothrombin and
thrombin probably play important roles in the inflammatory
process through the activation of PAR and microglia. Some
neurodegerative diseases are characterized by increased levels of
both active thrombin and PAR-1. Parkinson’s disease (PD) is
characterized by the selective loss of dopaminergic neurons in the
substantia nigra as well as the activation of microglia [31]. The
selected dopaminergic neuronal death has been shown as a result
of microglia activation by thrombin [32,33]. In AD, thrombin and
prothrombin are expressed in neurons and glial cells and
accumulated in senile plaques, reactive microglial cells, and
neurofibrillary tangles in brains [26]. In HD, aggregates of mutant
huntingtin exist in neurons, astrocytes, and microglia, resulting in
the altered neuronal-glial interactions [34]. The mutant huntingtin
may enhance the ability of microglia to produce proinflammatory
mediators (including IL-6, IL-8, and TNF-a) and contribute to
neurodegeneration in HD [20,34]. Since prothrombin was
thought to be involved in the inflammatory process through the
activation of PAR and microglia in the central nervous system
(CNS), the increased CSF prothrombin hints the inflammatory
process in HD. However, the mechanism of how prothrombin is
increased in CSF and how it is involved in the pathogenesis of HD
remain to be determined. It is worth to note that ratio of CSF
prothrombin/Alb was significantly proportional to the disease
severity, which may provide a potential biomarker indicating the
disease status. Since we did not examine if CSF prothrombin/Alb
ratio of other diseases are increased, whether the elevated
prothrombin is specific to HD remains to be clarified.
Apo A-IV is a glycoprotein synthesized mainly by the human
intestine and also in hypothalamus. Dense Apo A-IV staining has
been shown in the arcuate (ARC) hypothalamic nuclei, where Apo
A-IV was co-localized with pro-opiomelanocortin (POMC, a body
weight decreasing peptide), suggesting that the brain Apo A-IV
suppresses food intake probably by stimulating the ARC POMC
system [35]. Its intestinal and hypothalamic syntheses are
markedly stimulated by fat absorption. Apo A-IV could be up-
regulated in hypothalamus by leptin that acts tonically as an
afferent signal from adipose tissue to the brain, as part of a
negative feedback loop to regulate energy balance [36]. The
elevated level of Apo A-IV in CNS subsequently inhibits food
intake and regulates the long-term balance of body weight [37,38].
Increased Apo A-IV has been found in CSF of HD patients by
Fang et al. and its origin speculated by the authors may be from
peripheral blood [12]. However, a recent study suggested that the
circulating Apo A-IV in blood is unable to cross the blood brain
barrier (BBB) [36]. In contrast to the proposal presented by Fang
et al., our study shows that serum Apo A-IV is not increased and
Qalb in HD is not different from that in control, indicating intact
BBB, both of which suggest that the increased CSF Apo A-IV may
largely originate from the CNS rather than from peripheral blood,
although some proteins may be delivered into CNS by specific
transporters. In HD, weight loss is a characteristic feature in
advanced as well as early stage [7], but the mechanism is not
clearly known. A serum metabolic profile indicative of a pro-
catabolic phenotype in early HD preceding symptom onset has
been shown in both HD patients and transgenic mice [6].
Increased CART, a strong anorectic peptide involved in regulating
satiety and body weight, has been shown in CSF of HD patients,
also indicating a negative energy balance in HD [18]. The pro-
catabolic state in HD patients may account for the cachexia-like
features seen in the late disease stage and may also account for the
lower than expected weight of patients in the early disease stage.
Since Apo A-IV produced in CNS may exert its anorectic action,
the finding of increased CSF Apo A-IV in present study may
implicate an altered energy metabolism, which may be related
with the weight loss in HD patients. It is worth to note that the
BMI of HD patient is lower than that of the controls, although it
did not reach a statistical significance. The CSF Apo A-IV level,
however, was not correlated with BMI in HD patients, which
suggests that BMI may be affected by other factors than CNS Apo
A-IV only. Further HD animal studies are warranted to explore
the mechanism of how CSF Apo A-IV is increased and if it
correlates to weight loss in HD. Although the increased CSF Apo
A-IV was not found in patients with Guillain–Barre ´ syndrome,
since the number of the patients is small, further studies of a large
series of samples with other neurological diseases will be warranted
to verify whether the elevated Apo A-IV is specific to HD.
Figure 5. Linear regression of prothrombin/Alb to motor score, independence scale, and function capacity of UHDRS, respectively.
The ratio of prothrombin/Alb was significantly correlated to subscales of UHDRS, with a positive correlation to motor score (A, r=0.810, p=0.008) and
a negative correlation to independence scale (B, r=20.908, p,0.001) and functional capacity (C, r=20.891, p=0.001).
doi:10.1371/journal.pone.0015809.g005
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ed by infection or inflammation. It can bind irreversibly to
oxygenated and free hemoglobin (Hb) and thereby plays an
antioxidative activity [39]. The antioxidative effect is also observed
in CNS. It was found to be produced by oligodendrocytes and play
a protective role against Hb-mediated toxicity in intracerebral
hemorrhage [40]. Furthermore, haptoglobin was found to be
synthesized in reactive astrocytes in response to ischemic-
reperfusion injury in rats [41]. Additionally, elevated CSF
haptoglobin levels have be seen in idiopathic normal pressure
hydrocephalus, traumatic brain injury, Alzheimer’s disease,
multiple sclerosis, neuromyelitis optica, and Guillain-Barre ´
syndrome [42,43,44,45,46], and therefore may not be specific to
HD. In our study, CSF haptoglobin of HD patients was elevated
but the serum haptoglobin was not when compared with the
controls, which hints the increased intrathecal synthesis of
haptoglobin in HD. However, the CSF haptoglobin was not
correlated to the disease severity. Although the exact function of
haptoglobin in HD is unclear, the elevated haptoglobin may
represent the compensatory response to a serial inflammatory
cascade in CNS.
Compared with the findings of proteome analyses in HD CSF
published previously by Fang and colleagues where several
neuronal proteins were found to be reduced [12], our results
identified only three up-regulated protein molecules, which may,
in part, due to that we did not deplete CSF abundant protein
before 2-DE analysis, which could mask the small differences in
low abundant protein and thus the sensitivity of proteomic
techniques to identify proteins of biological interest could be
reduced. However, many proteins, no matter large or small, are
binding to or associated with high abundant protein such as
albumin. Therefore, depletion of high abundant protein may also
deplete some biologically important proteins. In this regard, we
chose not to deplete the high abundant protein before 2-DE
analysis [47]. Furthermore, our results are robust, because the
three proteins were further confirmed to be elevated in HD CSF
using western analysis or ELISA assay. Interestingly, the elevated
Apo A-IV, prothrombin, and haptoglobin were speculated to be
produced in central nervous system (CNS), based on intact BBB in
HD patients shown for the first time by the present study, although
it is possible that the increased proteins may be carried into CNS
by their transporters. Intact BBB in HD also supports that mutant
huntingtin induces parallel cell dysfunction in both CNS and
peripheral system. Future studies of BBB integrity in HD mice are
warranted to confirm our finding.
Our study results have provided insights into the pathogenesis of
HD and identified a few potential biomarkers for HD. However,
there are still some limitations. Our HD patients received variable
medications including tetrabenazine, amantadine, ubidecarenone,
neuroleptics (risperidone, haloperidol, and quetiapine), anticon-
vulsants (phenytoin, valproate and clonazepam), and antidepres-
sants (paroxetine and mirtazapine). Although there were no
previous studies exploring the interactions of medications to
prothrombin, Apo A-IV or haptoglobin, the possibility that the
medications could be a confounding variable can not be
completely excluded. Since our study enrolled a small number of
symptomatic patients, whether or not the results could be seen in
pre-symptomatic HD carriers remains to be clarified. Like most of
studies on CSF, it is difficult to obtain the CSF from healthy
individuals due to the ethical issue, which may add a confounding
factor to our results. In addition, there is no systematically
comparison of the changes in CSF of HD with other diseases, and
thus the specificity of the elevated protein in HD is not clear.
Hence, further studies with a large series of cases including pre-
symptomatic HD carriers are necessary to predict disease onset
and disease progression of HD.
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